Latest Advances in Lung Cancer Research

Fox Chase Cancer Center highlights advances in NSCLC treatment with immunotherapy and the promise of amivantamab for specific genetic mutations, alongside ongoing SCLC research.

Research shows combining KRAS inhibitors and immunotherapy could improve treatment for certain lung cancers, based on promising mouse studies.

Studies show smoking marijuana may harm lungs but lacks strong evidence linking it to lung cancer; research is challenged by marijuana’s legal history and variability.

Memorial Sloan Kettering researchers find a new SCLC subtype with normal Rb protein, potentially treatable with existing CDK4/6 inhibitor drugs.

Study shows nearly half of high-risk lung cancer screenings have delayed follow-up, with current smokers at higher risk of delays in care.

Global lung cancer rates have risen over 30 years with significant regional variations; researchers urge tailored interventions to address this persisting major health issue.

Opdivo plus chemo reduces death risk by 43% pre-surgery in NSCLC patients, leading to FDA approval, with broad patient eligibility regardless of PD-L1 levels.

Study finds White Americans 50% more likely to receive lung cancer screenings than Black Americans; health perception influences screening likelihood.

Merck’s Keytruda reduces early-stage lung cancer recurrence by 24% post-surgery, with plans for FDA approval submission, and shows a favorable safety profile.

Canadian researchers developed IPRO, a deep learning model for lung cancer care, enhancing prognosis by analyzing pre-treatment CT scans without manual input.